Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7707 results

  1. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  2. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]

    Technology appraisal guidance
    Discontinued

  3. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

    NICE guideline
    Last updated
    22 March 2021

  4. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC

    Medical technologies guidance
    In development

  7. Stye: antimicrobial prescribing

    Discontinued [GID-NG10167]

    Antimicrobial prescribing guideline
    Discontinued

  8. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

    Antimicrobial prescribing guideline
    Discontinued

  9. SILK artery reconstruction device (discontinued)

    Discontinued [GID-MT81]

    Medical technologies guidance
    Discontinued

  10. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

    NICE guideline
    Discontinued

  11. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  12. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  13. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  14. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  15. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued [GID-TAG409]

    Technology appraisal guidance
    Discontinued